JW Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

JW Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26M	Buy	+4,000	New	+$943K	0.4%	16
2019 Q1	–	Sell	-21,482	Closed	-$1.82M	–	19
2018 Q4	$1.82M	Hold	21,482	–	–	1.34%	12
2018 Q3	$3.68M	Hold	21,482	–	–	1.98%	11
2018 Q2	$2.78M	Hold	21,482	–	–	1.77%	13
2018 Q1	$2.21M	Hold	21,482	–	–	2.18%	12
2017 Q4	$1.83M	Hold	21,482	–	–	1.95%	14
2017 Q3	$1.82M	Hold	21,482	–	–	1.34%	19
2017 Q2	$1.63M	Sell	21,482 -6,412	-23%	-$449K	1.04%	20
2017 Q1	$1.84M	Sell	27,894 -29,952	-52%	-$1.97M	0.38%	22
2016 Q4	$3.67M	Sell	57,846 -11,362	-16%	-$717K	2.44%	11
2016 Q3	$4.41M	Buy	69,208 +11,221	+19%	+$824K	3.03%	9
2016 Q2	$4.31M	Hold	57,987	–	–	3.43%	10
2016 Q1	$3.87M	Hold	57,987	–	–	2.53%	12
2015 Q4	$3.92M	Hold	57,987	–	–	1.46%	16
2015 Q3	$3.1M	Buy	57,987 +539	+0.9%	+$32.7K	1.12%	21
2015 Q2	$3.62M	Buy	57,448 +1,313	+2%	+$71.6K	1.1%	18
2015 Q1	$2.7M	Buy	56,135 +3,674	+7%	+$141K	1.17%	22
2014 Q4	$1.74M	Buy	+52,461	New	+$1.71M	1.31%	17

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JW Asset Management's LGND Position: Q2 2026 in Review

JW Asset Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 4,000 shares worth $1.26M. The stake represents 0.4% of the portfolio and ranks #16 among its holdings. This is a return to the name: JW Asset Management previously reported a position in LGND as recently as Q4 2018.

JW Asset Management first reported a position in LGND in Q4 2014 and has held it in 18 quarters since. The position peaked at $4.41M in Q3 2016. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

JW Asset Management held 4,000 shares of Ligand Pharmaceuticals worth $1.26M as of Q2 2026.
Ligand Pharmaceuticals was a new JW Asset Management position in Q2 2026.
Ligand Pharmaceuticals made up 0.4% of JW Asset Management's portfolio in Q2 2026, its #16 holding.
JW Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 18 quarters since.
JW Asset Management's Ligand Pharmaceuticals position peaked at $4.41M in Q3 2016.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on JW Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.